Compare RPID & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | LNSR |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7M | 69.1M |
| IPO Year | 2021 | 2005 |
| Metric | RPID | LNSR |
|---|---|---|
| Price | $2.15 | $6.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 175.4K | 114.0K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $33,587,000.00 | ★ $58,435,000.00 |
| Revenue This Year | $19.12 | $10.06 |
| Revenue Next Year | $18.42 | $41.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.74 | 9.24 |
| 52 Week Low | $1.66 | $5.06 |
| 52 Week High | $4.94 | $13.43 |
| Indicator | RPID | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 64.94 | 50.80 |
| Support Level | $1.86 | $5.25 |
| Resistance Level | $2.17 | $6.34 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 100.00 | 43.02 |
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.